Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension

Erb, Carl; Lanzl, Ines; Seidova, Seid-Fatima; Kimmich, Friedemann

doi:10.1007/s12325-011-0038-9

Cited by 26 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tolerability had improved after the change to preservative-free tafluprost with a total of 85.7% of patients rating the tolerability as "very good" and "good." 40 …”

Section: Tafluprost Efficacy and Safety -Clinical Studiesmentioning

confidence: 99%

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The tolerability had improved after the change to preservative-free tafluprost with a total of 85.7% of patients rating the tolerability as "very good" and "good." 40 …”

Section: Tafluprost Efficacy and Safety -Clinical Studiesmentioning

confidence: 99%

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Even within existing drug classes, there are clear options for optimizing the balance between efficacy, safety, tolerability, potential quality concerns, impact on patient quality of life, and cost. Among prostaglandin analogues, for example, tafluprost provides efficacy in IOP lowering in various settings, with improvements in OSD symptoms and patient satisfaction when compared with latanoprost 88–98. Travoprost and tafluprost monotherapies were suggested to be cost-effective relative to latanoprost alone 99,100.…”

Section: Objectives and Methodsmentioning

confidence: 99%

<p>Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement</p>

Delgado¹,

Abdelrahman²,

Terahi³

et al. 2019

CEOR

View full text Add to dashboard Cite

Glaucoma is the leading cause of blindness in the developed and developing world. Not only is the clinical impact of this disease considerable, but associated economic and humanistic burdens – affecting patients, caregivers, and society – are substantial. Since glaucoma is an age-related disorder and populations in many developing countries are aging at a faster pace than in the developed world, increasing attention is being focused on ways to ameliorate the burdens of illness. In this paper, we examine the burdens of glaucoma with particular focus on developing countries, discuss some of the challenges that exist in delivering optimal glaucoma management within budget constraints, and bring into perspective how we could improve current healthcare systems, leverage technology, and strike an appropriate balance between cost and quality of care, thereby offering considerations to payors and policymakers in these countries that may result in longer-term cost savings, while concurrently striving to achieve the WHO Vision on the prevention of blindness and visual impairment.

show abstract

“…Erb et al evaluated “real-life” data on the efficacy and safety of preservative-free tafluprost from participating ophthalmologists. 37 Data were collected from 2123 patients with glaucoma or ocular hypertension receiving preservative- free tafluprost with or without a previous history of using other intraocular pressure-lowering agents 37. The preservative- free tafluprost lowered intraocular pressure from 19.5 ± 4.4 mmHg at baseline to 16.4 ± 2.9 mmHg after 6–12 weeks.…”

Section: Intraocular Pressure-lowing Effects In Human Subjectsmentioning

confidence: 99%

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Liu¹,

Mao²

2012

OPTH

View full text Add to dashboard Cite

Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

show abstract

Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension

Cited by 26 publications

References 25 publications

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

<p>Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement</p>

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Contact Info

Product

Resources

About